Abstract Severe coronavirus disease 2019 (COVID-19) is characterized by systemic hyper-
inflammation, acute respiratory distress syndrome, and multiple organ failure. Cytokine …

Hematological toxicity is the most common adverse event after chimeric antigen receptor
(CAR) T-cell therapy. Cytopenias can be profound and long-lasting and can predispose for …

Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several
cancers. While these immunotherapies have improved patient outcomes in many clinical …

PURPOSE To increase awareness, outline strategies, and offer guidance on the
recommended management of immune-related adverse events (irAEs) in patients treated …

Background A subset of patients with severe COVID-19 develop a hyperinflammatory
syndrome, which might contribute to morbidity and mortality. This study explores a specific …

Background T cell mediated hyperinflammatory responses such as cytokine release
syndrome (CRS) and immune effector cell associated neurotoxicity syndrome (ICANS) are …

Objectives To develop predictive criteria for COVID-19-associated cytokine storm (CS), a
severe hyperimmune response that results in organ damage in some patients infected with …

Hemophagocytic lymphohistiocytosis (HLH) is a syndrome describing patients with severe
systemic hyperinflammation. Characteristic features include unremitting fever, cytopenias …

SARS-CoV-2 infection is characterized by a protean clinical picture that can range from
asymptomatic patients to life-threatening conditions. Severe COVID-19 patients often display …

Objective Haemophagocytic lymphohistiocytosis (HLH) and macrophage activation
syndrome (MAS) are life-threatening systemic hyperinflammatory syndromes that can …